Post-transplant lymphoproliferative disorder treated with rituximab:case report

<正> Post-transplant lymphoproliferative disorder（PTLD）,arare disease,is characterized by an abnormalproliferation of lymphoid cells after solid organtransplantation.1 This complication is usually caused bythe immunosuppressive therapy following transplantation.Though the techniques of early detection and diagnosis ofthe disease are well established,treatment is not sostraightforward and poses a real challenge.At this time,options include anti-viral therapy,cytotoxicchemotherapy,cellular immunotherapy,and reduction ofimmunosuppression.But the effects of these therapies arenot satisfying.Rimximab,a chimeric monoclonalanti-CD20 antibody used for the treatment of B celllymphoma with a good effect,is rarely,especially in